Velaglucerase Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06720 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Steel syndrome | KG + DL |
| 2 | esophageal varices without bleeding | KG + DL |
| 3 | esophageal varices with bleeding | KG + DL |
| 4 | hypophosphatasia | KG + DL |
| 5 | Wolman disease with hypolipoproteinemia and acanthocytosis | KG + DL |
| 6 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 7 | cholesteryl ester storage disease | KG + DL |
| 8 | varicose disease | KG + DL |
| 9 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | KG + DL |
| 10 | proximal myopathy with extrapyramidal signs | KG + DL |
| 11 | reticular dysgenesis | KG + DL |
| 12 | familial apolipoprotein C-II deficiency | KG + DL |
| 13 | Charcot-Marie-Tooth disease | KG + DL |
| 14 | skeletal muscle disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.